|| 网站首页 | 英语听力自主训练中心 | 英语学习知识中心 | 英语学习音频资源 | 英语学习视频资源 | 英语学习留言簿 ||
|作者：英语点津 文章来源：China Daily 点击数：51 更新时间：2017/3/15|
A blood test for cancer can now show where in the body a tumour is growing, without the need for a painful biopsy.
'Liquid biopsies' are hoped to revolutionise cancer treatment, by identifying people with slow-growing tumours and those most in danger. They work by detecting the DNA released by dying tumour cells.
Now, for the first time, US scientists can also pinpoint the part of the body affected.
That is because the normal cells killed off by cancer also release DNA into the bloodstream, which has its own unique signature.
A team from the University of California San Diego have found the DNA patterns for 10 different types of tissue, including from the liver, lung and kidneys.
It means cancer patients who have symptoms shared across different types of cancer, such as bloating or sudden weight loss, could in future be diagnosed quickly and easily without needing a biopsy to remove part of an organ for testing.
Dr Catherine Pickworth, Cancer Research UK's science information officer, said: 'A biopsy can be invasive and unpleasant to go through, while any operation with an anaesthetic is risky.
This is potentially safer if it can be effective, which is why people are focusing on liquid biopsies.
Finding new ways to detect and treat cancer at an early stage is vital to help more people survive the disease. Looking for the DNA of cancer cells in the blood is an exciting idea, and this encouraging new approach might help reveal the location of tumours. '
The US researchers, whose study is published in Nature Genetics, analysed samples of tumours and blood samples from cancer patients to find markers for different organs in the blood.
They created a DNA database for the liver, intestine, colon, lung, brain, kidney, pancreas, spleen, stomach and blood.
Now the bioengineers know the normal cells, killed off when tumour cells compete with them for space and nutrients, also release a DNA signature, called CpG methylation haplotypes.
They were able to test which organ they came from by checking their diagnoses back against the cancer patients.
The researchers screened blood samples from individuals with and without tumours, looking for signals of the cancer markers and the tissue-specific methylation patterns.
The test works like a dual authentication process, with the combination of both signals required to assign a positive match.
The author added: 'This a proof of concept. To move this research to the clinical stage, we need to work with oncologists to further optimise and refine this method.'
|| 设为首页 | 加入收藏 | 联系站长 | 友情链接 | 网站公告 ||